REFERENCES
2. Tsuzuki S, Park SH, Eber MR, Peters CM, Shiozawa Y. Skeletal complications in cancer patients with bone metastases. Int J Urol 2016;23:825-32.
4. Casimiro S, Guise TA, Chirgwin J. The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol 2009;310:71-81.
5. Suva LJ, Washam C, Nicholas RW, Griffin R. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol 2011;7:208-18.
6. Hiraga T, Myoui A, Hashimoto N, et al. Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res 2012;72:4238-79.
7. Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res 2017;67:4157-63.
8. Kuchimaru T, Hoshino T, Aikawa T, et al. Bone resorption facilitates osteoblastic bone metastatic colonization by cooperation of insulin-like growth factor and hypoxia. Cancer Sci 2014;105:553-9.
9. Johnson RW, Sowder ME, Giaccia AJ. Hypoxia and bone metastatic disease. Curr Osteoporos Rep 2017;15:231-8.
10. Spencer JA, Ferraro F, Roussakis E, et al. Direct measurement of local oxygen concentration in the bone marrow of live animals. Nature 2014;508:269-73.
11. Reszka AA, Rodan GA. Nitrogen-containing bisphosphonate mechanism of action. Mini-Reviews Med Chem 2004;4:711-9.
12. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-21.
13. Dhesy-Thind S, Fletcher GG, Blanchette PS, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a cancer care ontario and american society of clinical oncology clinical practice guideline. J Clin Oncol 2017;35:2062-81.
14. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82.
15. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68.
16. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 2003;21:3150-7.
17. Gdowski AS, Ranjan A, Vishwanatha JK. Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials. J Exp Clin Cancer Res 2017;36:108.
18. Kelkar M, De A. Bioluminescence based in vivo screening technologies. Curr Opin Pharmacol 2012;12:592-600.
19. Yao Z, Zhang BS, Prescher JA. Advances in bioluminescence imaging: new probes from old recipes. Curr Opin Chem Biol 2018;45:148-56.
20. Paley MA, Prescher JA. Bioluminescence: a versatile technique for imaging cellular and molecular features. Physiol Behav 2019;176:139-48.
21. Nakajima Y, Kobayashi K, Yamagishi K, Enomoto T, Ohmiya Y. cDNA cloning and characterization of a secreted luciferase from the luminous Japanese ostracod, Cypridina noctiluca. Biosci Biotechnol Biochem 2004;68:565-70.
22. Katsuno Y, Hanyu A, Kanda H, et al. Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene 2008;27:6322-33.
23. Korpal M, Yan J, Lu X, Xu SW, Lerit DA, Kang YB. Imaging transforming growth factor-Β signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med 2009;15:960-6.
24. Kuchimaru T, Kataoka N, Nakagawa K, et al. A reliable murine model of bone metastasis by injecting cancer cells through caudal arteries. Nat Commun 2018;9:2981.
25. de Wet JR, Wood KV, DeLuca M, Helinski DR, Subramani S. Firefly luciferase gene: structure and expression in mammalian cells. Mol Cell Biol 1987;7:725-37.
26. Ando Y, Niwa K, Yamada N, et al. Firefly bioluminescence quantum yield and colour change by pH-sensitive green emission. Nat Photonics 2008;2:44-8.
27. Lorenz WW, McCann RO, Longiaru M, Cormier MJ. Isolation and expression of a cDNA encoding Renilla reniformis luciferase. Proc Natl Acad Sci U S A 1991;88:4438-42.
28. Kondoh G, Gao XH, Nakano Y, et al. Tissue-inherent fate of GPI revealed by GPI-anchored GFP transgenesis. FEBS Lett 1999;458:299-303.
29. Fujita K, Tanaka Y, Sho T, et al. Intracellular CO release from composite of ferritin and ruthenium carbonyl complexes. J Am Chem Soc 2014;136:16902-8.
30. Charles JP, Fuchs J, Hefter M, et al. Monitoring the dynamics of clonal tumour evolution in vivo using secreted luciferases. Nat Commun 2014;5:3981.
31. Park SH, Eber MR, Shiozawa Y. Models of prostate cancer bone metastasis. Methods Mol Viol 2019;1914:295-308.
32. Leclerc GM, Boockfor FR, Faught WJ, Frawley LS. Development of a destabilized firefly luciferase enzyme for measurement of gene expression. Biotechniques 2000;29:590-601.
33. Kang YB, he W, Tulley S, et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc natl Acad Sci U S A 2005;102:13909-14.
34. Henriquez NV, van Overveld PG, et al. Advances in optical imaging and novel model systems for cancer metastasis research. Clin Exp Metastasis 2007;24:699-705.
35. Brisset JC, Hoff BA, Chenevert TL, et al. Integrated multimodal imaging of dynamic bone-tumor alterations associated with metastatic prostate cancer. PLoS One 2015;10:e0123877.
36. Miki T, Yano S, Hanibuchi M, Sone S. Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5)cells in natural killer cell-depleted SCID Mice. Oncol Res 2000;12:209-17.
37. Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, imparing RAS membrain localization in prostate cancer cells. J Urol 2003;170:246-52.
38. Weiss HM, Pfaar U, Schweitzer A, Wiegand H, Skerjanec A, Schran H. Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos 2008;36:2043-9.
39. Hui AS, Bauer AL, Striet JB, Schnell PO, Czyzyk-Krzeska MF. Calcium signaling stimulates translation of HIF-α during hypoxia. FASEB J 2006;20:466-75.
40. Liao J, Schneider A, Datta NS, McCauley LK. Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res 2006;66:9065-73.
